17Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitors for the Treatment of Hormone-Related Diseases
申请人:Hartmann Rolf
公开号:US20100204234A1
公开(公告)日:2010-08-12
The invention relates to the use of non-steroidal 17beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment and prophylaxis of hormone-dependent, particularly estrogen-dependent, diseases. The invention further relates to suitable inhibitors and to a method for the production thereof.
Holdsworth; Lions, Journal and Proceedings - Royal Society of New South Wales, 1932, vol. 66, p. 459,468
作者:Holdsworth、Lions
DOI:——
日期:——
17BETA-HYDROXYSTEROID-DEHYDROGENASE-TYP1-INHIBITOREN ZUR BEHANDLUNG HORMONABHÄNGIGER ERKRANKUNGEN
申请人:Universität des Saarlandes
公开号:EP2131826A2
公开(公告)日:2009-12-16
Haptens, hapten conjugates, compositions thereof and method for their preparation and use
申请人:Kosmeder Jerome W.
公开号:US20100297725A1
公开(公告)日:2010-11-25
A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.